Codexis, Inc.
Codexis, Inc. is listed today as Codexis, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2019 | $50 M | Private placement after listing | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Codexis, Inc., its revenue in fiscal 2025 came from these product and service lines: Research and development revenue $44.36 million (63%).
Annual report (SEC XBRL) · Dec 2025
Codexis, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2019).
SEC Form D · Jun 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2019
Products and services#
No products or services of Codexis, Inc. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Biomedical Sciences Investment Fund Pte Ltd. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| CMEA Ventures Life Sciences 2000, Civil Law Partnership | Venture capital | not stated | not stated | Held Series B, D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Cmea Ventures Life Sciences 2000 LP | Venture capital | not stated | not stated | Held Series B, D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| CMEA Ventures LS Management 2000, L.P. | Venture capital | not stated | not stated | Held Series B, D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| EDB Investments Pte Ltd. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Equilon Enterprises LLC | Other | not stated | not stated | Held Series D, E and F preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Maxygen Inc | Company | not stated | not stated | Held Series A, B and D preferred stock, 10% owner, director (Form 3, 2010) | SEC Form 3 |
| Royal Dutch Shell PLC | Company | not stated | not stated | Held Series D, E and F preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Codexis, Inc. shares, as of Sep 30, 2026.
- Aberdeen Group plc$15 M9.85%
- BlackRock, Inc.$12 M7.59%
- Telemark Asset Management, LLC$11 M7.16%
- Millennium Management LLC$7 M4.35%
- Vanguard Capital Management LLC$6 M3.96%
- Ameriprise Financial Inc$4 M2.79%
- Nantahala Capital Management, LLC$4 M2.37%
- Opaleye Management Inc.$4 M2.36%
- Geode Capital Management, LLC$3 M2.26%
- D. E. Shaw & Co., Inc.$2 M1.63%
- State Street Corp$2 M1.49%
- Jacobs Levy Equity Management, Inc$2 M1.41%
- Vanguard Portfolio Management LLC$2 M1.30%
- Private Advisor Group, LLC$2 M1.10%
- Acadian Asset Management LLC$2 M1.02%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Gordon Sangster | Executive officer | Jun 2019 |
| John Nicols | Executive officer | Jun 2019 |
| Bernard Kelley | Director | Jun 2019 |
| Byron Dorgan | Director | Jun 2019 |
| David Smith | Director | Jun 2019 |
| Dennis Wolf | Director | Jun 2019 |
| John Nicols | Director | Jun 2019 |
| Kathleen Glaub | Director | Jun 2019 |
| Pam Cheng | Director | Jun 2019 |
| Patrick Yang | Director | Jun 2019 |
| Thomas Baruch | Director | Jun 2019 |
About
American protein engineering company.
Went public since 2010. Its SEC number is that of a company listed on a stock exchange.